


AMENDMENTS TO THE CLAIMS

Please amend the claims as follows. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-37 (Canceled)

38. (New) A compound of the Formula (I):



(I)

wherein:

X is phenyl;

Y is 2-pyridyl;

A is C₀ alkyl,

B is C₀ alkyl,

X is optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups; A is -C₀alkyl, B is -C₀alkyl,

Y is optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or

-C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups;

W is -C₃₋₇cycloalkyl, -heteroC₃₋₇cycloalkyl, -C₀₋₆alkylaryl, or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

Z is -C₃₋₇cycloalkyl, -heteroC₃₋₇cycloalkyl, -C₀₋₆alkylaryl, or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

R¹, R², and R³ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

R⁴ is -C₁₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

R⁵, R⁶, and R⁷ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

R⁸ is -C₁₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

R⁹ and R¹⁰ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents; and
any N may be an N-oxide;
or a pharmaceutically acceptable salt thereof.

39. (New) The compound according to Claim 38 wherein:

X is phenyl, which is optionally substituted with 1-5 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups.

40. (New) The compound according to Claim 38 wherein:

Y is 2-pyridyl, which is optionally substituted with 1-4 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups.

41. (New) The compound according to Claim 38 wherein:

W is -C₀₋₆alkylaryl, or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents.

42. (New) A compound which is selected from the group consisting of:

1-methyl-3-[3-(5-pyridin-2-yl-2*H*-tetrazol-2-yl)phenyl]imidazolidin-2-one;

2-[2-(4-pyridin-2-ylphenyl)-2*H*-tetrazol-5-yl]pyridine;

2-[2-(4-pyridin-4-ylphenyl)-2*H*-tetrazol-5-yl]pyridine;

2-{2-[3-(1*H*-imidazol-1-yl)phenyl]-2*H*-tetrazol-5-yl}pyridine;

2-[2-(2-pyrazin-3-ylphenyl)-2*H*-tetrazol-5-yl]pyridine;












2-[2-(4-morpholin-3-ylphenyl)-2*H*-tetrazol-5-yl]pyridine;






















2-{2-[3-(2*H*-tetrazol-5-yl)phenyl]-2*H*-tetrazol-5-yl}pyridine; and


2-pyridin-2-yl-5-(5-pyridin-2-yl-2*H*-tetrazol-2-yl)benzonitrile;















or a pharmaceutically acceptable salt thereof.


43. (New) A compound which selected from the group consisting of:


| | | |
|---|---|--|
| |  |  |
|  |  |  |
|  |  |  |
|  |  |  |









| | | |
|---|---|--|
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |










| | | |
|---|---|--|
|  |  |  |
|  |  |  |
| | |  |
|  |  | |
| |  |  |
|  |  |  |
















| | | |
|---|---|--|
| |  |  |
|  |  |  |
|  | | |
| |  | |
| |  | |







| | | |
|--|---|--|
| |  <p>Chemical structure of 1-(4-(4-(benzyloxy)phenyl)-5-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)benzene. The structure features a central benzene ring substituted at the 1-position with a 1H-1,2,4-triazole ring, at the 4-position with a 4-(benzyloxy)phenyl group, and at the 5-position with a pyridin-2-yl group.</p> | |
| |  <p>Chemical structure of 1-(4-(4-(1H-1,2,4-triazol-1-yl)phenyl)-5-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)benzene. The structure features a central benzene ring substituted at the 1-position with a 1H-1,2,4-triazole ring, at the 4-position with a 4-(1H-1,2,4-triazol-1-yl)phenyl group, and at the 5-position with a pyridin-2-yl group.</p> | |
| |  <p>Chemical structure of 1-(4-(4-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-5-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)benzene. The structure features a central benzene ring substituted at the 1-position with a 1H-1,2,4-triazole ring, at the 4-position with a 4-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl group, and at the 5-position with a pyridin-2-yl group.</p> | |







| | | |
|--|---|--|
| |  | |
| |  | |
| |  | |
| |  | |







| | | |
|--|---|--|
| | | |
| |  <p>Chemical structure of 4-(4-(benzotriazol-2-yl)-3-fluorophenyl)benzyl alcohol. It features a benzotriazole ring system connected to a 3-fluorophenyl ring, which is further connected to a 4-(benzyl hydroxymethyl)phenyl ring.</p> | |
| |  <p>Chemical structure of 4-(4-(benzotriazol-2-yl)-3-methoxyphenyl)toluene. It features a benzotriazole ring system connected to a 3-methoxyphenyl ring, which is further connected to a 4-(toluyl)phenyl ring.</p> | |
| |  <p>Chemical structure of 4-(4-(benzotriazol-2-yl)phenyl)methyl methyl sulfide. It features a benzotriazole ring system connected to a phenyl ring, which is further connected to a 4-(methylthiomethyl)phenyl ring.</p> | |













| | | |
|--|--|--|
| |  <chem>c1ccncc1-c2nn[nH]n2-c3ccc(Cl)c(Cl)c3</chem> | |
|  <chem>Cc1ccc(cc1)-c2nn[nH]n2-c3ccncc3</chem> |  <chem>COc1ccc(cc1)-c2nn[nH]n2-c3ccc(Cl)c(Cl)c3</chem> | |
|  <chem>Fc1ccc(cc1)-c2nn[nH]n2-c3ccncc3</chem> |  <chem>c1ccc(cc1)-c2nn[nH]n2-c3ccc(Oc4ccccc4)cc3</chem> | |










| | | |
|---|---|--|
|  |  | |
|  |  | |
|  |  | |


| | | |
|---|---|--|
|  |  | |
|  |  | |
|  |  | |


| | | |
|---|---|--|
|  |  | |
|  |  | |
|  |  | |










| | | |
|---|---|--|
|  |  |  |
|  |  |  |
|  |  |  |













| | | |
|---|---|--|
|  |  |  |
|  |  |  |
|  |  |  |




















| | | |
|---|---|--|
|  |  |  |
|  |  |  |
|  |  |  |
















| | | |
|---|---|--|
|  |  |  |
|  |  |  |
|  |  |  |




| | | |
|---|--|--|
|  <chem>Clc1ccc(cc1-c2ccc(cc2-n3nn[nH]3-c4cccnc4)Cl</chem> | |  <chem>CCOC1=CC=C(C=C1-c2ccc(cc2-n3nn[nH]3-c4cccnc4)</chem> |
|  <chem>Fc1cc(F)ccc1-c2ccc(cc2-n3nn[nH]3-c4cccnc4)</chem> | |  <chem>CC(=O)Nc1ccc(cc1-c2ccc(cc2-n3nn[nH]3-c4cccnc4)</chem> |
|  <chem>Clc1cc(Cl)ccc1-c2ccc(cc2-n3nn[nH]3-c4cccnc4)</chem> | |  <chem>Clc1cc(Cl)cc(C=C1-c2ccc(cc2-n3nn[nH]3-c4cccnc4))</chem> |

| | | |
|--|---|---|
|  <chem>Oc1ccc(cc1)-c2ccc(cc2)-c3nn[n+]([n-])c4ccccc4n3</chem> | |  <chem>c1ccc(cc1)-c2ccccc2-c3ccc(cc3)-c4ccc(cc4)-c5ccccc5-c6nn[n+]([n-])c7ccccc7n6</chem> |
|  <chem>Cc1cc(C)ccc1-c2ccc(cc2)-c3nn[n+]([n-])c4ccccc4n3</chem> |  <chem>c1ccc2c(c1)oc3ccccc3c2-c4ccc(cc4)-c5nn[n+]([n-])c6ccccc6n5</chem> |  <chem>c1ccc2c(c1)oc3ccccc3c2-c4ccc(cc4)-c5nn[n+]([n-])c6ccccc6n5</chem> |
|  <chem>Cc1cc(C)ccc1-c2ccc(cc2)-c3nn[n+]([n-])c4ccccc4n3</chem> |  <chem>COc1cc(ccc1-c2ccc(cc2)-c3nn[n+]([n-])c4ccccc4n3)-c4ccc(Cl)cc4</chem> |  <chem>[O-][N+](=O)c1ccc(cc1)-c2ccc(cc2)-c3ccc(cc3)-c4ccc(cc4)-c5nn[n+]([n-])c6ccccc6n5</chem> |

| | | |
|--|--|---|
|  <chem>CCc1ccccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |  <chem>Fc1cc(F)ccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |  <chem>COc1cc(C)ccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |
|  <chem>CC(=O)c1ccccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |  <chem>COc1cc(Cl)ccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |  <chem>COc1cc(Cl)c(Cl)cc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |
|  <chem>NC(=O)c1ccccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |  <chem>COc1ccccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |  <chem>COc1cc(OC)ccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |
|  <chem>Oc1ccccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |  <chem>COc1cc(OC)ccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |  <chem>COc1cc(O)ccc1-c2ccccc2-n3nn[nH]3-c4cccnc4</chem> |





or a pharmaceutically acceptable salt thereof.

44. (New) A pharmaceutical composition comprising the compound of Claim 38, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

45. (New) A pharmaceutical composition comprising the compound of Claim 42, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

46. (New) A pharmaceutical composition comprising the compound of Claim 43, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.